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The results of Western blot analysis for the four monoclonal antibodies AHF2:l. AHF2:2, AHF2:3 and AHF2:4 with fibrinogen and its plasmin degradation products under reducing ( K ) and non-reducing ( N K ) conditions are shown. The tentative locations of the epitopes bound by these antibodies are based on areas of common amino acid sequences for fibrinogen and its degradation products. AHF2: 1 reacted with fibrinogen separated in SDS/polyacrylamide-gel electrophoresis under reducing conditions followed by Western blotting on to nitrocellulose to reveal two bands of molecular mass 60.5 kDa and 64.4 kDa. These bands correspond to the A-a bands of fibrinogen which can have different molecular masses due to varying degrees of proteolytic degradation [ 11. Western blotting of pooled Dand E-fragments showed reaction for AHF2:l with the E-fragment and a band of molecular mass 61.7 kDa. The nature of the latter band is unclear. Since AHF2:l recognizes both the A-a chain and the E-fragment of fibrinogen, the tentative location of the epitope involved can be narrowed down to amino acid residues 1-78 of the A-a chain which are common to both the A-a chain and the E-fragment.
Chains
AHF2:2 failed to bind to any chains of fibrinogen when examined by Western blot analysis of reduced fibrinogen in SDS/polyacrylamide-gel electrophoresis, indicating that the epitope( s) recognized by this antibody is structural and present only in the native protein. Probing of fibrinogen and its early plasmin degradation products under non-reducing conditions revealed bands corresponding to fibrinogen and the X-, Y-and D-fragments. It did not detect the E-fragment. Western blot analysis using AHF2:4 showed that this antibody reacted with the B-/3 chain of fibrinogen under reducing conditions and was also seen to react with the D-fragment under non-reducing conditions. The tentative location of the epitope involved can therefore be narrowed to amino acid residues 134-46 1 o f the B-@ chain of fibrinogen.
The four monoclonal antibodies described here may find a role in the assay of plasma levels of fibrinogen and its degradation products. It has been noted that elevated levels of fibrin degradation products in patients with unstable angina may be indicative of the onset of acute myocardial infarction [S] . The administration of anti-fibrinolytic agents at the time of observing such an increase in fibrin degradation products may help to prevent the onset of the infarction. A second potential application is in the localization of fibrin deposits (clots) in vivo and the targetting of fibrinolytic therapy.
Growth-associated protein (GAP-43, also termed B50, F1, pp46 or p57) is a fast axonally transported phosphoprotein whose synthesis and transport appear to be selectively enhanced during periods of axonal growth, both in development and regeneration (for review see [ 11). GAP-43 is a protein kinase C substrate and is probably involved in modulating intracellular calcium signalling. Phosphorylation of GAP-43 by protein kinase C strongly inhibits binding of the protein to calmodulin [2] .
In an attempt to raise specific anti-( GAP-43) antibodies N-terminal and C-terminal tetradecapeptides of the GAP-43 sequence [3] were synthesized using the Fmoc-polyamide solid phase procedure of Sheppard modified for the use of pentafluorophenylester-activated derivatives 141. The Nterminal peptide sequence had one substitution in the GAP-43 sequence, where tyrosine replaced on aspartate at position 13, to provide a site for possible iodination. The synthesized peptides were purified by reverse-phase h.p.1.c. and conjugated to bovine serum albumin (BSA) using either carbodiimide or glutaraldehyde. After dialysis the peptidc-BSA conjugates were emulsified in complete Freund's adjuvant and injected intramuscularly into rabbits. Subsequent booster immunizations used an emulsion of conjugate and incomplete Freund's adjuvant. After several boosts, the rabbits were bled by the ear vein and serum prepared. To affinity purify the C-terminal-directed antiserum, an affinity column consisting of the C-terminal peptide cross-linked to CH-Sepharose (Pharmacia) was prepared according to the manufacturer's recommendations. An immunoglobulin (1gG)-enriched fraction was prepared from one of the rabbits immunized with the C-terminal peptide using a protein A The specificity of the N-and C-terminal antisera were examined by Western blotting against a GAP-43-enriched fraction from 14-day-old rat brain (prepared essentially as described in IS]). Fresh rat brain tissue was homogenized in 0.32 M-SUCTOSC' and centrifuged at 1000 rev./min for 10 min. The supernatant was then centrifuged at 20 000 rev./min for 30 min. The pellet was resuspended in low ionic strength Tris/HCl ( 10 mM, pH 7.4) and frozen and thawed. After centrifugation. the pellet was washed twice in high salt (0.5 MNaCl in 1 0 mM-Tris/HCI, pH 7.4). After a final centrifugation (20 000 rev./min), this pellet was then extracted in an alkaline solution (0.1 M-Na2-C0,, pH 11.5). The supernatant containing extracted GAP-43 was recovered after a further centrifugation at 20 000 rev./min, dialysed against 10 mM-Tris/HCl, pH 7.4, divided into aliquots and stored at -70°C until used.
GAP-43-enriched extracts were separated on SDS/polyacrylamide gels, transferred on to nitrocellulose and then blocked with 5% (w/v) gelatin. After blocking, the nitrocellulose sheets were incubated with the rabbit anti-(GAP-43 peptide) antibodies (either N-or C-terminal) for 48 h at 4°C. The immune reaction was located by incubation with a second biotinylated anti-( rabbit) antibody (60 min at room temperature) and an avidin-biotin-peroxidase conjugate (Vector Labs, Peterborough). The peroxidase enzyme was visualized using diaminobenzidine and hydrogen peroxide.
As shown in Fig. 1 , the unpurified N-terminal-directed antiserum visualized one immunoreactive band at approximately 46 kDa, with a few minor bands of higher molecular mass. The unpurified C-terminal-directed antisera detected one major band at 40 kDa and a fainter band at a slightly lower molecular mass level ( -37.5 kDa). In addition, there is a further minor immunoreactive band at 80 kDa. These minor bands were not visualized by the affinity-purified ('-terminal antiserum (Fig. 1 ) .
The localization of the major immunoreactive band visualized by the C'terminal antiserum was consistent with that detected by antibodies raised against purified GAP-43 (kind gift of Dr W. H. Gispen, Utrecht) or a recombinant GAP-43 (kind gift of Dr M. B. Willard, Stanford). The minor band is believed to be a major proteolytic product of GAP-43/B50, termed B60 [6J.
Immunocytochemical studies using the antibodies revealed the presence of large amounts of GAP-43-like immunoreactivity in the developing rat brain and spinal cord. GAP-43-like immunoreactivity also accumulated in the spinal cord after transsection or in the spinal ganglia after peripheral nerve lesion.
These results indicate clearly that short synthetic peptides based on the GAP-43 sequence can be used to produce antibodies specific for GAP-43.
Antibodies to various protein fractions in cows' milk protein in human serum have been of interest for many years. Results from previous studies have indicated that the presence of Abbreviation used: ELISA, enzyme-linked immunosorbent assay. these antibodies strongly support the hypothesis that cows' milk protein is absorbed across the intact gut wall eliciting the observed antibody response [ 11. Further research into the quantity of milk antibodies found in different groups of individuals and their significance regarding various disease states is required before such levels can be used for clinical diagnosis purposes.
A number of methods have been reported to measure total IgG antibodies against the a-casein component in cows' milk. We have developed a quantitative assay using an
